If panic attacks have sent you searching for the vagus nerve, here is what the research says. Two small studies in this set enrolled people with panic disorder: a one-session cold-face lab study and an open-label implanted vagus nerve stimulation pilot that included one person with panic disorder. No randomized trial of vagus nerve stimulation for panic disorder was found. The NHS panic disorder page lists talking therapies, especially cognitive behavioural therapy, and medicine as the treatments for panic disorder.
For a wider view beyond panic, our complete guide covers what vagus nerve stimulation trials do and do not establish about anxiety.
Affiliate disclosure: You will find affiliate links on this page. This site may receive a commission on purchases made through them.
Quick facts about the vagus nerve and panic, as of 2026-11-11
| Fact | Detail | Source |
|---|---|---|
| Panic attack symptoms | Racing heartbeat, sweating, chest pain, shortness of breath, dizziness and fear of dying | NHS panic disorder page |
| Typical attack length | Most attacks last 5 to 20 minutes | NHS panic disorder page |
| Panic treatments the NHS lists | Talking therapies, especially CBT, and medicine such as SSRIs or tricyclic antidepressants | NHS panic disorder page |
| Panic-disorder cold-face study (2021) | 32 people, 16 with panic disorder, in one lab session; heart rate fell about 30 to 35 beats per minute in both groups | Kyriakoulis et al., Frontiers in Psychiatry |
| Implanted VNS pilot (2008) | 11 adults recruited across OCD, PTSD and panic disorder; 3 acute responders at 12 weeks | George et al., Brain Stimulation |
| Consumer vagus devices | Sold as general wellness products for stress and sleep, per their makers | Maker pages, quoted below |
| FDA approvals for implanted VNS | Epilepsy (1997), depression (2005), stroke rehabilitation (2021) | FDA device records |
| Medicare coverage for VNS in depression | Covered only inside a CMS-approved randomized, placebo-controlled trial with at least 1 year of follow-up | CMS National Coverage Determination 160.18 |
Where is the vagus nerve, and what does it do?
The vagus nerve is the tenth cranial nerve. A vagus nerve and fear extinction review describes it as “the longest and most widely distributed visceral sensory nerve in the body,” arising from the medulla in the brainstem. A 2026 extension article by Gabriela Murza says it originates in the brainstem, extends to the abdomen and branches out to organs such as the heart, lungs and stomach. (extension article on vagal nerve stimulation)
Is the vagus nerve sympathetic or parasympathetic?
It is part of the parasympathetic system. Psychology Today puts the two sides simply: “Your sympathetic nervous system revs you up. Your parasympathetic nervous system calms you down.” The extension article says the parasympathetic nervous system “helps bring the body back to a state of calm after a stressful event.” The review adds that the vagus nerve, as part of the parasympathetic system, slows the sympathetic response.
How does the vagus nerve connect to panic attacks?
The NHS describes panic disorder as sudden attacks of panic or fear, often with no obvious trigger. Its NHS panic disorder page lists racing heartbeat, sweating, chest pain, shortness of breath, dizziness and fear of dying, and says most attacks last 5 to 20 minutes. Research on the vagus nerve asks whether the body’s calming side can be engaged on purpose. The studies below test that idea in different ways.
What do the studies on the vagus nerve and panic show?
Most of this research is on related problems, such as generalized anxiety, PTSD and stress. Two studies in this set enrolled people with panic disorder. The table lists each study with its numbers.
| Study | Who was studied | Compared with | Length | What it found |
|---|---|---|---|---|
| 2021 cold-face panic study (Kyriakoulis et al., Frontiers in Psychiatry) | 32 people: 16 with panic disorder, with or without agoraphobia, and 16 healthy controls | Four conditions in random order, including a 30-second cold facial immersion; no sham arm | One laboratory session | Significant reductions in physiological and cognitive panic symptoms in the panic group after cold facial immersion; heart rate fell significantly, about 30 to 35 beats per minute in both groups (Discussion); self-reported anxiety and panic were lower |
| George 2008 implanted pilot (George et al., Brain Stimulation) | 11 adults recruited with treatment-resistant OCD, PTSD or panic disorder; the abstract lists 7 OCD, 2 PTSD and 1 panic disorder | Open-label, no sham; surgically implanted VNS added to stable medication | 12-week acute phase; long-term follow-up, with 4 patients still on VNS four years after implant | 3 acute responders on the Hamilton Anxiety scale at 12 weeks (response = 50% or more improvement); significant improvement at 14 of 18 quarters in long-term follow-up; the authors say the open data suggest further double-blind studies may be warranted |
| Richer 2022 cold face study (Richer et al., Scientific Reports) | 28 healthy adults | Randomized between two groups facing a laboratory stress task; one group had the Cold Face Test | One laboratory stress task | Both groups were equally stressed; the cold-face group showed better recovery in heart rate and HRV and a lower cortisol response |
| Ferreira 2024 student anxiety trial (Ferreira et al., Frontiers in Integrative Neuroscience) | University health-science students aged 18 to 25 with Beck Anxiety Inventory scores of 7 or higher; the abstract says 42 participants and the anxiety statistics use 20 | Active transcutaneous auricular VNS vs sham | Three sessions on alternate days over one intervention week; followed up at 2 weeks | The active group’s Beck Anxiety Inventory score fell from an average of 9.3 to 4.1 right after and 5.1 at 2 weeks (p < 0.05); the sham group did not change; adverse events: none reported. The main outcomes were jaw-muscle activity and pain threshold, with anxiety as one measure |
| Jackowska 2025 community trial (Jackowska et al., Biological Psychology) | 70 community adults (28 men), mean age 49.33, range 18 to 75 | Early and late groups, each active or sham | Daily sessions for 14 days in all groups | In community adults with subthreshold affective symptoms (not panic disorder), single-blind: active beat sham in the early-phase groups, but not the late-phase groups, for anxiety symptoms and perceived stress; no advantage for depressive symptoms. The authors write that the results “tentatively indicates” a possible benefit at population level |
| Lin 2026 sleep meta-analysis (Lin et al., Psychology, Health & Medicine) | People with sleep disorders, from 14 randomized trials; 11 in the pooled analysis | Pooled transcutaneous auricular VNS trials | Trials searched to 10 January 2025 | Pooled anxiety-related scale score: SMD -0.53 (95% CI -0.74 to -0.32). Side effects were mild and mostly resolved on their own. The authors say the findings “should be considered preliminary” |
| Benzouak 2025 PTSD review (Benzouak et al., BJPsych Open) | People with trauma- and stressor-related disorders, in 7 randomized studies | Narrative synthesis; no pooled numbers | Searched to December 2023 | The authors say VNS as a treatment for PTSD “is limited and does not meet clinical expectations”; overall certainty of evidence “very low” |
| Lai 2025 protocol (Lai et al., Heliyon) | 60 adults with generalized anxiety disorder, planned | Active vs sham stimulation | 8 weeks, planned | A protocol: it describes a plan, not a result |
The two panic studies used different tools. The 2021 cold-face study tested cold facial immersion, not a vagus device. The George 2008 pilot tested a surgically implanted system in a handful of people, and only one of them had panic disorder.
A separate mouse study looked at stress, not panic. In a mouse study of vagus nerve and stress, 20 of 36 mice given social defeat stress became stress-susceptible. The authors report that chronic vagus nerve stimulation restored behavior-relevant brain oscillations in those mice. That work was done in mice.
Do vagus nerve stimulators work for panic?
For panic disorder specifically, the research in this set is the 2021 cold-face study and the 2008 implanted pilot. The FDA records for vagus devices list uses in epilepsy, depression, stroke rehabilitation and headache. None of them is panic disorder.
| Use | Device | FDA record | Decision or letter date |
|---|---|---|---|
| Partial-onset seizures in epilepsy | Implanted VNS Therapy System | FDA record for VNS epilepsy approval | July 16, 1997 |
| Long-term treatment of chronic or recurrent depression in adults who have not responded to four or more antidepressant treatments | Implanted VNS Therapy System | FDA approval letter for depression | July 15, 2005 |
| Arm motor function during rehabilitation therapy after chronic ischemic stroke | Vivistim (implanted) | FDA record for Vivistim | August 27, 2021 |
| Specific headache uses, including cluster headache and migraine | gammaCore Sapphire, non-invasive, prescription | FDA record for gammaCore | November 27, 2018 |
These clearances belong to the gammaCore device alone, and the stroke system is implanted and used with rehabilitation therapy. FDA labels mean different things. A 510(k) is a clearance, which FDA describes as showing a device is “substantially equivalent” to one already legally marketed. A PMA is, in FDA’s words, “the most stringent type of device marketing application.” The FDA device approvals and clearances page sets out each route.
Medicare coverage for implanted VNS in depression is narrow. The CMS coverage decision for VNS says FDA-approved VNS devices for treatment-resistant depression are covered only within a CMS-approved double-blind, randomized, placebo-controlled trial with at least 1 year of follow-up. Outside such a trial, VNS for that use is non-covered.
In epilepsy, the Epilepsy Foundation VNS guide reports about a 28% decrease in seizures in the first 3 months, 36% after 6 months and 58% after 4 years. Those are the Foundation’s summary figures, and it says the device is FDA-approved for adults and children 4 years and older.
What do the consumer neck and ear devices say about themselves?
Consumer devices are sold as general wellness products. Their makers’ own wording is reported below, as they state it.
| Device | What the maker says it is for | Regulatory wording on its pages |
|---|---|---|
| Truvaga (neck device) | “to support a balanced nervous system” | “Truvaga devices are considered a wellness product and are not covered by health insurance.” |
| Pulsetto (neckband) | “assist them in relaxing” | “Pulsetto is considered a general wellness device”; the maker says the device is “FCC-certified” |
| Apollo Neuro (wearable that sends vibrations) | “to help manage stress, challenging life transitions, and to promote a healthy lifestyle” | “is a consumer wellness device and does not require FDA approval for sale” |
| Nuropod (ear device) | “scientifically proven to modulate the vagus nerve”; for “adults looking to improve their health and performance” | “Third party certified device” |
| gammaCore Sapphire (hand-held, prescription) | Specific headache uses, per the FDA record | “available by prescription only,” per the manufacturer’s 2017 release |
Nurosym says it “is a certified device (CE) in Europe.” The FCC equipment authorization page describes authorization for radio-frequency devices and their potential to cause interference.
One stress study on a consumer neck device comes from Pulsetto. Its PDF, “Cervical Vagus Nerve Stimulation for Stress Reduction,” was printed from Pulsetto’s website, and its acknowledgements say “Pulsetto Proof of Concept gave funding for the project.” It enrolled 15 healthy people, each with one active session and one placebo session, and measured heart rate variability only. The LF/HF ratio fell by an average 64.5% after stimulation and 6.8% after placebo. The placebo was a session with no stimulation. The PDF’s abstract says “five patients” while its body says 15 people.
What are the side effects, and who should skip these devices?
The Cleveland Clinic VNS guide lists these side effects for implanted VNS. Consumer devices carry their own lists, which are shown after the table.
| Source | Side effects or risks listed |
|---|---|
| Cleveland Clinic VNS guide (implanted VNS) | Coughing, hoarseness, voice change, neck or throat pain, shortness of breath, trouble speaking or swallowing, headache. Serious ones include vocal cord paralysis, infection and device complications. |
| Truvaga, per its maker | “less than 5% of participants” had mild effects such as site discomfort or redness, muscle twitching, localized face, head or neck pain (including toothache), mild headache or mild dizziness |
| Lin 2026 sleep meta-analysis | Only mild side effects, mostly resolved on their own |
| Ferreira 2024 student anxiety trial | Adverse events: none reported |
The Cleveland Clinic says external products “can’t match the frequencies and voltages used in implanted devices,” and that “The long-term side effects of commercial VNS devices are yet to be fully known.” The extension article notes that the Cleveland Clinic warns people with heart conditions or low blood pressure to be cautious, because vagus nerve stimulation can cause fainting or bradycardia.
| Device | Who the maker says should skip it |
|---|---|
| Truvaga | Anyone with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device |
| Pulsetto | Heart condition, irregular heartbeat, high or low blood pressure, or a past serious cardiac event; seizures, fainting or a diagnosed neurological condition; neck surgery, serious head injury or unusual neck anatomy; any active electronic implant, metal implant or stent in or near the neck; pregnancy; cancer treatment; broken or damaged skin on the neck. Intended for adults aged 18 and over |
| Nuropod | Cervical vagotomy; severe low resting heart rate; permanent implanted metallic or electronic device or jewelry close to the ear; pregnancy; children; severe coronary disease or a heart attack within 5 years. Listed as contraindications unless a health professional advises otherwise |
| gammaCore | Active implanted devices; a metallic stent, bone plate or bone screw at or near the neck; using another device at the same time, such as a TENS unit or portable electronic device |
Can I stimulate my own vagus nerve?
Consumer devices are the makers’ products, and each comes with its own skip list. The extension article notes that medical VNS requires professional evaluation. Without a device, the NHS and the extension article both point to calm, slow routines. The NHS advises breathing slowly and deeply during a panic attack. Its self-help list for generalized anxiety disorder includes calming breathing exercises, yoga or pilates, regular exercise and enough sleep. The extension article says deep breathing, meditation and massage “show promise” because they slow heart rate and breathing, and that non-invasive techniques like deep breathing are generally safe.
Which treatments do agencies list for panic disorder?
| Option | What the agency lists | Source |
|---|---|---|
| Talking therapies | Talking therapies, especially cognitive behavioural therapy (CBT), for panic disorder | NHS panic disorder page |
| Medicine for panic | SSRIs or tricyclic antidepressants; in some cases pregabalin or clonazepam | NHS panic disorder page |
| Timing | Antidepressants can take 2 to 4 weeks to start working and up to 8 weeks to work fully | NHS panic disorder page |
| Generalized anxiety disorder | Psychotherapy such as cognitive behavioral therapy and acceptance and commitment therapy; medicine such as SSRIs, SNRIs, benzodiazepines and buspirone | NIMH generalized anxiety disorder page |
Ask a primary care clinician, or a psychiatrist or psychologist, which of these fits your symptoms.
What the research does not show
For panic disorder itself, the research here is one implanted-device pilot with one panic patient and one lab session with 16 people who have panic disorder, so none of these approaches replaces the NHS treatments listed above.
For epilepsy and depression, the extension article says VNS therapy “often takes weeks or months to notice improvements.”
Common mix-ups to avoid
If you are reading about cannabis for anxiety, our indica vs sativa for anxiety guide covers that research, and our CBD gummies for sleep and anxiety guide covers the research on sleep and anxiety products. The table sorts out the other common mix-ups.
| What you may have seen | What the sources say |
|---|---|
| “Vagus nerve stimulation works instantly for mental health issues.” | The extension article says VNS therapy for epilepsy and depression often takes weeks or months to notice improvements. |
| “Cold exposure instantly stimulates the vagus nerve and reduces anxiety.” | The extension article lists this as a popular message. It says cold exposure slows heart rate and engages the parasympathetic nervous system. |
| Gargling or humming for anxiety | The extension article says gargling, humming and singing “are not a standalone treatment for anxiety or depression.” |
| “FDA cleared” and “FDA approved” mean the same thing | FDA treats clearance (510(k)) and approval (PMA) as separate routes. |
| “FCC-certified” means approved for health use | The FCC describes equipment authorization for radio-frequency devices and their potential to cause interference. Pulsetto says its FCC status means the device is “approved for well-being use.” |
| Stress studies in healthy people show anxiety relief | The Richer 2022 study enrolled 28 healthy adults and measured heart rate, HRV and cortisol. |
| A sleep trial shows anxiety results | The 2026 meta-analysis pooled trials in people with sleep disorders; its anxiety-scale result comes from that sleep population. |
Questions to settle before your next step
- Do your attacks match the NHS description: racing heartbeat, sweating, chest pain, shortness of breath, dizziness or fear of dying, with most lasting 5 to 20 minutes?
- Have you talked with a primary care clinician about talking therapies and medicine? A psychiatrist or psychologist can assess panic disorder in more depth.
- If you are considering a device, read its label first. “Wellness,” “cleared,” “approved,” “CE” and “FCC” mean different things, as the table above shows.
- Check the skip list against your own history: heart conditions, implanted devices, pregnancy and recent neck surgery.
- Ask the company for the regulatory documents for the exact model you are considering.
- Read any new claim about a device the way you would read a headline: check who was studied and how many people took part.
By the Global MH Summit Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.